Retraction Note to: Physcion 8-O- β -glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1

Editorial Office of Pharmacological Reports¹

Published online: 2 December 2020
© Maj Institute of Pharmacology Polish Academy of Sciences 2020

Retraction to: Pharmacological Reports 69 (2017) 36–44
<https://doi.org/10.1016/j.pharep.2016.09.012>

The Editor in Chief retracted this article [1] because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. After publication, overlap was detected with figures in articles submitted and published within a close time frame.

In Fig. 2A the image for MDA-MB-231 at 0 dose appears to be very similar to that in Fig. 2A in (2) published earlier.

In Fig. 2A the image for MDA-MB-231 at dose 50 appears to be very similar to that in Fig. 3A in (3, now retracted) published earlier.

Figure 6B appears to contain images that have been published elsewhere with different labels: Fig. 9E (4).

The authors were unable to provide raw data. The Editor-in-Chief therefore no longer has confidence in the integrity of the data in this article.

All authors agree to this retraction.

References

1. Chen X, Guo H, Li F, et al. Physcion 8-O- β -glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1. *Pharmacol Rep.* 2017;69:36–44. <https://doi.org/10.1016/j.pharep.2016.09.012>.
2. Ding Z, Xu F, Tang J, Li G, Jiang P, Tang Z, Wu H. Physcion 8-O- β -glucopyranoside prevents hypoxia-induced epithelial-mesenchymal transition in colorectal cancer HCT116 cells by modulating EMMPRIN. *Neoplasma.* 2016;63(3):351–61.
3. Retracted: Gao H, Zhong F, Xie J, Peng J, Han Z. PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling [retracted in: *Am J Cancer Res.* 2020 Jul 01;10(7):2201]. *Am J Cancer Res.* 2016;6(2):425–439 (Published 2016 Jan 15).
4. Wang T, Jiang Y, Chu L, Wu T, You J. Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma [published correction appears in *Am J Cancer Res.* 2019 Feb 01;9(2):455–457]. *Am J Cancer Res.* 2017;7(4):999–1015.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1016/j.pharep.2016.09.012>.

✉ Editorial Office of Pharmacological Reports

¹ <https://www.springer.com/journal/43440>